Twist Bioscience (TWST) Q4 2026 earnings summary

Executive summary

• FY26 revenue reached a record $459.4M, up 22%; gross margin rose to 52.4%, and Q4 adjusted EBITDA was positive $2.2M, the first positive quarter.

• Revenue grew sequentially for 15 consecutive quarters; FY27 guidance calls for $550M–$560M revenue and positive adjusted EBITDA, alongside continued investment in capacity and new products.

Financial highlights

• Q4 revenue was $126.6M, up 28% YoY; FY26 revenue was $459.4M versus $376.6M, up 22%.

• Q4 gross margin was 53.1%, versus 51.3% a year earlier; FY26 gross margin was 52.4%, versus 50.7% in FY25.

• Q4 adjusted EBITDA was positive $2.2M versus a $7.8M loss; FY26 adjusted EBITDA loss improved to $35.9M from $46.9M.

• FY26 GAAP net loss was $130.2M, or $2.08 per diluted share, versus $77.7M, or $1.30; Q4 net loss narrowed to $20.6M from $27.1M.

Outlook and guidance

• FY27 revenue guidance is $550M–$560M, representing 21% YoY growth at midpoint; assumptions include $100M from AI drug discovery.

• FY27 gross margin guidance is 52.5%–53%, with positive adjusted EBITDA expected for the full year; DSPS and NGS are expected to grow sequentially.

• Q1 FY27 revenue guidance is $130M–$132M, or 26% YoY growth at midpoint; DSPS and NGS are each expected to grow more than 25% YoY.

• FY27 CapEx is expected to be ~$75M, excluding landlord-funded improvements; the FY27–FY28 plan includes ~$150M CapEx and more than $30M in landlord-funded improvements.

• Existing facilities are expected to support more than $1B in annual revenue at scale; FY27 growth is expected to exceed 20%.